NewsDialy
A Roche drug has established a new treatment standard for KRAS-driven lung cancer, STAT+ reported, marking a significant moment in an oncology target that has long resisted effective therapy.
The news lands as the broader biotech sector's rally continues to build momentum.
What KRAS-Driven Lung Cancer Means KRAS is a gene that, when mutated, acts as a jammed accelerator inside cancer cells — telling them to divide without stopping.
KRAS mutations are among the most common drivers of lung cancer, and for decades the protein the gene encodes was considered undruggable, its surface offering no obvious pocket for a small molecule to grip.
Keep reading